Paolo Fiorina, MD, PhD is an endocrinologist. He is Director, International Center for T1D, Romeo ed Enrica Invernizzi Pediatric, University of Milan, Italy; Professor of Endocrinology, L. Sacco Hospital, University of Milan; Chief of Division of Endocrinology, ASST Sacco-Fatebenefratelli, Milan, Italy and Lecturer on Pediatrics, Boston Children’s Hospital, Harvard Medical School. He is actively involved in the Grant Committee of JDRF, Medical Science Review Committee (MSRC) for Islet Biology and Transplantation, Transplant Meeting Committee at the San Raffaele Hospital (Milan), American Heart Association (AHA), and American Society of Transplantation (AST).
He published over 140 peer-reviewed manuscripts (5700+ citations, h-index 44). He is focused in devising new immune-based preventive and therapeutic strategies for autoimmune diseases.
His publication track record includes seminal contribution to the field of immunotherapy for the treatment of type 1 diabetes and of transplantation and stem cells to prevent and treat autoimmune diabetes and allograft rejection.
AurorA-TT is a Technology Transfer Intermediation Company established in 2017 based in Milan, Italy. We identify promising scientific breakthroughs from academia and research centers in Italy and partner with academia, research institutions and biotech companies based globally.
We do invest in pre-seed and seed projects to bridge the gap between basic research and industrial drug development with industrial discipline. Successful projects either become assets for the creation of stand-alone companies, partnership with financial investors, biotech and pharma companies, or translate into agreements of varying nature with synergic partners.
Alessandra Biffi, MD, is a pediatric hematologist and stem cell transplant physician. She is Professor of Pediatrics, University of Padua and Chief of the Pediatric Onco-hematology Unit of Padua Hospital; until September 2018, Director of the Gene Therapy Program, Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Principal Scientist at the Harvard Stem Cell Institute, Chair of the Scientific Review Committee for Gene Therapy at Boston Children’s Hospital, and Associate Professor of Pediatrics Harvard Medical School.
She published over 60 peer-reviewed manuscripts and textbook chapters. She is actively involved in gene therapy trials for neurological genetic diseases, hemoglobinopathies and immunodeficiencies and has developed a unique expertise in the pre-clinical development and clinical testing of hematopoietic stem cell gene therapy approaches.
Her publication track record includes seminal contribution to the field of cell and gene therapy.
Paolo Rizzardi, MD, internist, is Co-Founder and Managing Partner of AurorA-TT, a Technology Transfer initiative fully focused in the biotech sector, and Co-Founder, Chairman&CEO of Altheia Science. He combines a strong scientific background with managerial skills gained in substantially contributing to successfully develop biotechnology companies and to achieve the market approval of advanced therapy medicinal products in the cell&gene therapy and oncology field. After spending more than 10 years in academia in Italy, UK, and Switzerland in developing programs for innovative immune-based/vaccination strategies in patients with HIV/AIDS, he worked for more than 15 years in the cell&gene therapy biotech sector, developing a unique expertise in R&D, CMC, clinical and business development, development, engineering, and IP from target validation to market approval.
He published over 90 peer-reviewed manuscripts and textbook chapters (4500+ citations, h-index 32), including seminal contribution to the field of immunopathogenesis and innovative treatment of HIV infection.
Rita Milazzo, PhD, is a senior researcher with over 10 years of experience in the field of hematopoietic stem cell (HSC) gene therapy for neurodegenerative diseases.
She advanced in her carrier working with the San Raffaele Telethon Institute for Gene Therapy in Milano (SR-TIGET), where she focused on the identification of critical factors enhancing HSC-based transplant procedures for diseases with severe nervous system involvement.
Her research contributed to the development of innovative strategies for the treatment of neurological genetic diseases and in the translation of pre-clinical data into the design of human clinical trials as in the case of metachromatic leukodystrophy.
Her work is published in peer-reviewed journals in the field of cell and gene therapy.
Pierluigi Paracchi is Co-Founder and Venture Consultant of AurorA-TT, a Technology Transfer initiative fully focused in the biotech sector, and Co-Founder, Board Member of Altheia Science.
He has more than 15 years of experience as Venture Capitalist and Biotech Entrepreneur. He was Founder & CEO of Quantica, the first Italian VC firm exclusively dedicated to research and academic spin-out companies and Venture Consultant at Sofinnova Partners. He was investors and Board Member at EOS – Ethical Oncology Science, acquired by Clovis Oncology for 470M.
He is Co-Founder and CEO of Genenta Science, spin-out from San Raffaele Hospital: gene therapy for tumor treatment; Board Member at Assobiotec and Chairman of the SMEs group.
Moufida Ben Nasr M, PhD, is an immunologist. She is Research Fellow at Nephrology Division, Boston Children’s Hospital, Harvard Medical School.
She published over 20 peer-reviewed manuscripts. She is focused in immunology and stem cell biology to develop strategies for transplantation and the treatment of hematological malignancies and autoimmune diseases.
Her publication track record includes important contribution to the field of immunobiology and immunotherapy of type 1 diabetes, identifying mechanisms to be targeted to prevent the attack of autoreactive T cells.